Hims & Hers Health, Inc. (NYSE:HIMS) trended on Wednesday after the company outlined an expanded weight-management push tied to branded GLP-1 access.
Expands Access To Popular Weight-Loss Drugs
The company says it is collaborating with Novo Nordisk (NYSE:NVO) to soon offer access to the only FDA-approved GLP-1 weight-loss pill, alongside injectable Wegovy in all dosages, and it also plans to offer Ozempic injections in all available dosages at cash-pay prices starting at $149 a month. It also launched an “exclusive pre-launch waitlist” to give customers priority access to availability updates, transparent pricing, and the debut of the strategic collaboration.
Focuses On Long-Term Care And Outcomes
Hims & Hers says providers will be able to prescribe programs that pair FDA-approved GLP-1 medications with 24/7 access to a care team and education across nutrition and physical wellness, positioning the offering as long-term care rather than a quick fix. The company also points to clinical outcomes, citing a 71-week, double-blind, placebo-controlled trial of oral semaglutide 25 mg, in which 27.9% of participants lost at least 20% of body weight at week 64 (vs 3.1% for placebo), with an average weight loss of 13.6% (vs 2.4% for placebo).
Technical Analysis
HIMS is trading 31.2% above its 20-day SMA but 21.7% below its 100-day SMA, and shares are down 20.67% over the past 12 months, which fits a “bounce inside a bigger downtrend” profile. Within the $13.74 to $70.43 52-week range, the stock is positioned closer to its lows than its highs, and the 50-day SMA remains below the 200-day SMA after the death cross in December.
RSI is at 62.69, in neutral territory, suggesting the recent rebound hasn’t reached overheated levels. The MACD is bullish, with the MACD line at 0.6719 above the signal line at -0.7768, and the positive histogram (1.4488) shows that upside momentum has been improving.
The combination of an RSI above 50 and a bullish MACD suggests mixed momentum, with short-term strength battling a weaker longer-term trend.
Earnings & Analyst Outlook
Looking further out, the next major catalyst for the stock arrives with the May 4, 2026 (estimated) earnings report.
- EPS Estimate: 2 cents (Down from 20 cents YoY)
- Revenue Estimate: $618.44 million (Up from $586.01 million YoY)
- Valuation: P/E of 49.0x (Indicates premium valuation relative to peers)
Analyst Consensus & Recent Actions: The stock has a Hold rating and an average price target of $31.23. Recent analyst moves include:
- Leerink Partners: Market Perform (Raises Target to $25.00) (Mar. 16)
- Barclays: Overweight (Raises Target to $29.00) (Mar. 11)
- Citigroup: Upgraded to Neutral (Raises Target to $24.00) (Mar. 10)
Benzinga Edge Rankings
Below is the Benzinga Edge scorecard for Hims & Hers Health, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Weak (Score: 5.81) — The stock is showing limited trend strength versus the broader market despite the recent bounce.
- Value: Weak (Score: 2.89) — The shares screen as expensive on traditional value factors, which can amplify pullbacks when risk appetite fades.
- Growth: Neutral (Score: 44.65) — Growth is present but not strong enough in the scorecard to offset weak value and momentum signals.
The Verdict: Hims & Hers Health. Benzinga Edge’s signal reveals a premium-valued setup with weak momentum and only moderate growth support. For longer-term bulls, the chart needs to hold the $24.00 area and keep rebuilding above the 50-day trend before the move looks more durable.
Top ETF Exposure
- SPDR Portfolio S&P 600 Small Cap ETF (NYSE:SPSM): 0.60% Weight
- SPDR S&P 600 Small Cap Growth ETF (based on S&P SmallCap 600 G (NYSE: SLYG): 1.17% Weight
- Vanguard S&P Small-Cap 600 Index Fund ETF (NYSE:VIOO): 0.64% Weight
Significance: Because HIMS carries meaningful weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock.
Price Action
HIMS Stock Price Activity: Hims & Hers Health shares were down 3.76% at $24.04 at the time of publication on Wednesday, according to Benzinga Pro data.
Image via Shutterstock